GC Cell

GC Cell EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of GC Cell (144510.KQ) as of Nov 2, 2026 is 0.63 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was 6.56 % — a change of -90.39% (lower).

EBIT/Assets

0.63 %

YoY

-90.39%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of GC Cell is 2023 0.63 % . Operating Income to Assets Ratio (EBIT/Assets) of GC Cell was 2022 6.56 % . It decreases by -90.39% lower compared to the previous year.

The GC Cell EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2016
2.74 KRW
Jan 1, 2017
1.59 KRW
Jan 1, 2018
0.76 KRW
Jan 1, 2019
-5.60 KRW
Jan 1, 2020
8.42 KRW
Jan 1, 2021
5.64 KRW
Jan 1, 2022
6.56 KRW
Jan 1, 2023
0.63 KRW
The GC Cell EBIT/Assets history
YEAREBIT/AssetsYoY
0.63 %-90.39%
6.56 %+16.28%
5.64 %-33.05%
8.42 %-250.54%
-5.60 %-836.60%
0.76 %-52.28%
1.59 %-41.88%
2.74 %-85.66%
19.09 %-5.70%
20.25 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GC Cell Stock analysis

What does GC Cell do? GC Cell Corp generates revenue through four business segments. The Specimen Testing Service segment offers sample testing, clinical trial support, and veterinary testing services to clients in healthcare and research sectors. The Cell Therapy segment provides cell culture solutions and technology transfer services to biotechnology firms. The Cord Blood Storage segment delivers cord blood storage services primarily to expectant parents and medical institutions. The Other Business segment handles bio-logistics services and related operations for healthcare providers. The company's revenue streams are derived from direct contracts with healthcare organizations, biotech companies, and individual clients seeking specialized testing and storage solutions. Clients include hospitals, research institutions, and private individuals requiring cord blood preservation. The firm's business model focuses on providing specialized services within the life sciences sector without relying on external partnerships or third-party platforms. GC Cell Corp's product offerings are tailored to specific industry needs, with each segment targeting distinct client groups. The Specimen Testing Service segment serves clients needing laboratory analysis, while the Cell Therapy segment supports biotech innovation through technology transfer. The Cord Blood Storage segment caters to consumer demand for personal health preservation, and the Other Business segment facilitates logistics for medical supply chains. GC Cell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GC Cell stock

Operating Income to Assets Ratio (EBIT/Assets) of GC Cell is 0.63 % in 2023.

Operating Income to Assets Ratio (EBIT/Assets) of GC Cell changed from 6.56 % to 0.63 %, representing a -90.39% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) GC Cell since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s GC Cell with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — GC Cell

All Key Metrics — GC Cell